Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Long-Term Investments (2016 - 2025)

Surgery Partners' Long-Term Investments history spans 10 years, with the latest figure at $234.0 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 8.64% year-over-year to $234.0 million; the TTM value through Dec 2025 reached $234.0 million, up 8.64%, while the annual FY2025 figure was $234.0 million, 8.64% up from the prior year.
  • Long-Term Investments for Q4 2025 was $234.0 million at Surgery Partners, up from $229.4 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $234.0 million in Q4 2025 and bottomed at $88.7 million in Q4 2021.
  • The 5-year median for Long-Term Investments is $191.0 million (2022), against an average of $175.2 million.
  • The largest annual shift saw Long-Term Investments surged 114.54% in 2022 before it dropped 3.26% in 2023.
  • A 5-year view of Long-Term Investments shows it stood at $88.7 million in 2021, then soared by 114.54% to $190.3 million in 2022, then dropped by 3.26% to $184.1 million in 2023, then increased by 17.0% to $215.4 million in 2024, then rose by 8.64% to $234.0 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Long-Term Investments are $234.0 million (Q4 2025), $229.4 million (Q3 2025), and $220.2 million (Q2 2025).